- Home
- INVE vs PRLD Comparison
INVE vs PRLD Comparison
Compare INVE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | PRLD |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 69.1M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVE | PRLD |
|---|---|---|
| Price | $3.70 | $2.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.50 | $4.00 |
| AVG Volume (30 Days) | 38.6K | ★ 495.7K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,015,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $2.86 | $0.61 |
| 52 Week High | $4.07 | $4.22 |
Technical Indicators
Market Signals| Indicator | INVE | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.42 | 61.78 |
| Support Level | $3.52 | $2.37 |
| Resistance Level | $3.90 | $3.00 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 67.16 | 68.14 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.